DE69001503T2 - D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen. - Google Patents

D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen.

Info

Publication number
DE69001503T2
DE69001503T2 DE9090104875T DE69001503T DE69001503T2 DE 69001503 T2 DE69001503 T2 DE 69001503T2 DE 9090104875 T DE9090104875 T DE 9090104875T DE 69001503 T DE69001503 T DE 69001503T DE 69001503 T2 DE69001503 T2 DE 69001503T2
Authority
DE
Germany
Prior art keywords
alanine
memory
cycloserin
improving
mixture containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE9090104875T
Other languages
English (en)
Other versions
DE69001503D1 (de
Inventor
Alexis A Cordi
Michael R Jans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of DE69001503D1 publication Critical patent/DE69001503D1/de
Publication of DE69001503T2 publication Critical patent/DE69001503T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
DE9090104875T 1989-03-15 1990-03-15 D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen. Expired - Fee Related DE69001503T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32427989A 1989-03-15 1989-03-15
US07/473,241 US5061721A (en) 1989-03-15 1990-02-06 Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Publications (2)

Publication Number Publication Date
DE69001503D1 DE69001503D1 (de) 1993-06-09
DE69001503T2 true DE69001503T2 (de) 1993-09-09

Family

ID=26984373

Family Applications (1)

Application Number Title Priority Date Filing Date
DE9090104875T Expired - Fee Related DE69001503T2 (de) 1989-03-15 1990-03-15 D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen.

Country Status (17)

Country Link
US (1) US5061721A (de)
EP (1) EP0387867B1 (de)
JP (1) JP2963720B2 (de)
KR (1) KR900013961A (de)
AT (1) ATE88890T1 (de)
AU (1) AU624917B2 (de)
CA (1) CA2010635C (de)
DE (1) DE69001503T2 (de)
DK (1) DK0387867T3 (de)
ES (1) ES2055197T3 (de)
FI (1) FI901289A0 (de)
GR (1) GR3008225T3 (de)
IE (1) IE64130B1 (de)
IL (1) IL93562A (de)
NO (1) NO901198L (de)
NZ (1) NZ232809A (de)
PT (1) PT93424B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
EP1060750B1 (de) * 1993-03-29 2005-12-07 Queen's University At Kingston Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable Salze zur Behandlung von Amyloidosis
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
WO1996015788A1 (en) * 1994-11-23 1996-05-30 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
JPH11501619A (ja) * 1995-02-15 1999-02-09 ベアーズデン バイオ，インコーポレイテッド アルキルカルボキシアミノ酸−カイネートレセプターのモジュレーター
JP2002513380A (ja) 1996-07-22 2002-05-08 コグネティックス・インコーポレイテッド コナントキンの使用
JP2001507924A (ja) 1996-07-22 2001-06-19 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション コナントキン類
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
EP1844769A3 (de) 1998-04-14 2010-02-10 The General Hospital Corporation Verfahren zur Behandlung neuropsychischer Erkrankungen
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
WO2002078629A2 (en) * 2001-03-29 2002-10-10 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
CN1527813A (zh) * 2001-04-02 2004-09-08 О 作为治疗剂的抗氧化剂硝基氧和亚硝氮碳基
CA2744115A1 (en) * 2001-05-02 2002-11-07 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
EP1487542A1 (de) * 2002-03-15 2004-12-22 H. Lundbeck A/S Verwendung von asc-1-hemmern zur behandlung von neurologischen und psychiatrischen erkrankungen
EA010430B1 (ru) * 2003-05-27 2008-08-29 Форест Лэборэтериз, Инк. Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
EP1660634A4 (de) * 2003-08-08 2009-02-18 Burnham Inst P16-vermittelte regulation von nmda-rezeptoren
EP1703907A4 (de) 2003-12-29 2009-03-25 Jason Mcdevitt Zusammensetzungen und verfahren zur behandlung von rezidivierenden krankheiten
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
CA2604052C (en) 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
PL3851447T3 (pl) 2006-10-12 2024-03-04 Bellus Health Inc. Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy
US20100113453A1 (en) * 2007-04-10 2010-05-06 Mcdevitt Jason P Sublingual Formulations of D-Cycloserine and Methods of Using Same
WO2010033757A1 (en) 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
TWI544923B (zh) * 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
AU2011215704B2 (en) 2010-02-11 2015-07-23 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
JP5689026B2 (ja) * 2010-06-17 2015-03-25 株式会社 資生堂 水中油型乳化皮膚化粧料
WO2012104852A1 (en) * 2011-01-31 2012-08-09 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
EP2931291B1 (de) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenonbehandlung als zusatz für psychotherapie bei psychiatrischen erkrankungen
CA2899010A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2015009785A (es) 2013-01-29 2016-04-04 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
BR112015018087B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
MX2015009772A (es) 2013-01-29 2016-05-31 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
EP3490993B1 (de) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spirolactam-nmda-modulatoren und verfahren zu deren verwendung
EP3490994B8 (de) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam und bis-spiro-lactam nmda rezeptor modulatoren und deren verwendung
EP3490992B1 (de) 2016-08-01 2023-03-22 Aptinyx Inc. Spöiro-lactam nmda rezeptor modulatoren und deren verwendung
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
EP3427729A1 (de) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid zur behandlung von epileptischen erkrankungen, störungen oder zuständen
CA3089561A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428730A (en) * 1967-06-30 1969-02-18 Hamao Umezawa Antibacterial mixture of o-carbamyl-d-serine and d-4-amino-3-isoxazolidone
US4031231A (en) * 1974-06-13 1977-06-21 Merck & Co., Inc. Antibacterial composition comprising 3-fluoro-D-alanine or deutero analog in combination with auto-antagonist inhibitor
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers

Also Published As

Publication number Publication date
PT93424A (pt) 1990-11-07
IE64130B1 (en) 1995-07-12
GR3008225T3 (de) 1993-09-30
IL93562A0 (en) 1990-11-29
NZ232809A (en) 1992-05-26
CA2010635A1 (en) 1990-09-15
CA2010635C (en) 2001-03-06
ATE88890T1 (de) 1993-05-15
DE69001503D1 (de) 1993-06-09
KR900013961A (ko) 1990-10-22
NO901198D0 (no) 1990-03-14
ES2055197T3 (es) 1994-08-16
PT93424B (pt) 1996-08-30
DK0387867T3 (da) 1993-06-01
IL93562A (en) 1996-01-31
FI901289A0 (fi) 1990-03-15
EP0387867B1 (de) 1993-05-05
EP0387867A1 (de) 1990-09-19
NO901198L (no) 1990-09-17
IE900921L (en) 1990-09-15
JPH03148221A (ja) 1991-06-25
US5061721A (en) 1991-10-29
AU624917B2 (en) 1992-06-25
AU5073490A (en) 1990-09-20
JP2963720B2 (ja) 1999-10-18

Similar Documents

Publication Publication Date Title
DE69001503D1 (de) D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69426351T2 (de) Verfahren zur Modifizierung des Wachstums von Körperhaaren und/oder Haaren und hierfür verwendbare Zusammensetzungen
DE69204639D1 (de) Verwendung von Modafinil zur Herstellung eines antiischämischen Arzneimittels.
ES2063060T3 (es) Benzamida contra enfermedades cognoscitivas.
ZA886459B (en) Use of bezafibrate for treating diabetes
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE68900917D1 (de) Behandlungsverfahren fuer zyanid und/oder sonstige oxidierbare stoffe enthaltenden abwaessern.
ATE143804T1 (de) Zusammensetzung zur behandlung von mastitis und metritis
ATE174220T1 (de) Verwendung von leflunomid zur hemmung von interleukin 8
DE58902451D1 (de) (s)-emopamil zur anwendung bei der behandlung von migraene.
DE68902511T2 (de) Dermato-kosmetische zusammensetzung zur behandlung des hautalterns und zur verhuetung von falten.
ATE124727T1 (de) Verfahren zur behandlung von häuten und so erhaltene häute.
ATE174217T1 (de) Verwendung von leflunomid zur hemmung von interleukin 1 alpha
ATE87614T1 (de) Methoden zur verwendung von 2-isopropyl-2phenylaminovaleriansaeurenitrilen als immunosupressoren und vasodilatoren.
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
ZA901995B (en) Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee